Prognostic implications of chemoresistance-sensitivity assays for XXXX .

@entity1 @entity66 @entity5 @entity1138 @entity344 @entity189 @entity14 @entity1487
A major problem with pharmacologic treatments for @entity5 is the unpredictable nature of the clinical response. Therefore, many @entity1 are treated but few benefit from chemotherapy. Selection of @entity1 for drug treatment would greatly benefit both responders and nonresponders. @entity1138 (MMC) and @entity1487 ( @entity1487 ) are important drugs widely used in the treatment of @entity1 with @entity344 . In a prospective study, an in vitro chemoresistance-sensitivity assay (CR-SA) was performed for 95 @entity1 at the time of surgery for peritoneal @entity189 from @entity14 . Following cytoreductive surgery, all of these @entity1 had minimal-to-moderate @entity66 . All @entity1 were treated with the same chemotherapy regimen regardless of the results of the in vitro assay in the postoperative period. Clinical status of @entity1 was correlated to the assay predictions, and the results were statistically evaluated. When resistance was correlated with outcome, there was no statistical difference. In addition, the mean percentage of growth inhibition was not increased when responders and nonresponders were compared. Finally, more @entity1 who had > or = 95% in vitro growth inhibition of @entity5 did not survive than did those with < or = 95% growth inhibition. The in vitro test did not predict sensitivity or resistance to @entity5 when regional chemotherapy was administered in a clinical setting of peritoneal @entity189 .
